<SEC-DOCUMENT>0001776985-22-000003.txt : 20220110
<SEC-HEADER>0001776985-22-000003.hdr.sgml : 20220110
<ACCEPTANCE-DATETIME>20220110085816
ACCESSION NUMBER:		0001776985-22-000003
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220109
FILED AS OF DATE:		20220110
DATE AS OF CHANGE:		20220110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		22519940

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kcrescendocollaborat.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib44ed0ec39654f8e963ece3b8b002f12_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF JANUARY 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">On January 10, 2022, BioNTech SE (the &#8220;Company&#8221;) and </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Crescendo Biologics Ltd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (&#8220;Crescendo&#8221;), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that the two companies have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The press release is attached hereto as Exhibit 99.1.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; January 10, 2022 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="ex991crescendocollaboratio.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:0.35pt;padding-right:0.35pt;text-align:justify"><font><br></font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991crescendocollaboratio.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4eb04cb48d6e4ad98bc9bfcd3d4cd7b7_1"></div><div style="min-height:120.83pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.240%"></td><td style="width:0.1%"></td></tr><tr style="height:69pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-right:2.75pt"><img alt="image.jpg" src="image.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:120px"></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:115%">BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Collaboration leverages BioNTech&#8217;s proprietary multimodal immunotherapy expertise with Crescendo&#8217;s proprietary Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> V</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">H</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> platform to develop</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against targets selected by BioNTech</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">BioNTech will hold exclusive worldwide development and commercialization rights to all immunotherapies arising from the collaboration</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">as well as research funding, and will be eligible to receive development, regulatory and commercial milestone payments up to a total of more than $750 million, plus tiered royalties on global net sales</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NEW YORK, USA and CAMBRIDGE, UK, January 10, 2022 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; BioNTech SE (Nasdaq&#58; BNTX) and </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Crescendo Biologics Ltd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;Crescendo&#8221;), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. The initial term of the discovery collaboration is three years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Crescendo will contribute its unique, proprietary, transgenic platform to deliver fully human heavy-chain antibody domains (Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> V</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">H</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) against targets nominated by BioNTech. Humabodies represent a novel class of therapeutics that retain the high-affinity binding and specificity of conventional therapeutic antibodies while providing additional advantages such as small size, enhanced tissue and tumor penetration, stability, and molecular simplicity due to the lack of a light chain. In particular, the modular nature of Humabodies make them ideally suited for the development of multi-target immunotherapies. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;Crescendo&#8217;s platform provides excellent properties for exploiting novel targets and target combinations which we believe has great potential for the development of multi-specific mRNA and engineered cell-based therapies in a variety of disease areas,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. &#8220;We are excited to begin working with Crescendo to further strengthen and expand our multimodal immunotherapy portfolio and deliver breakthrough precision medicines for patients.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;To collaborate with BioNTech and their world-class team is a transformational opportunity for Crescendo. We are looking forward to further leveraging our clinically validated Humabody V</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">H</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> platform within mRNA therapeutics to develop better treatment options for patients,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Theodora Harold, Chief Executive Officer at Crescendo Biologics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the terms of the agreement, Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech, as well as research funding for the period of the collaboration. BioNTech will be responsible for global development and hold exclusive worldwide commercialization rights on any products arising from the collaboration. Crescendo will be eligible to receive development, regulatory and commercial milestones up to a total of more than $750 million, in addition to tiered royalties on global net sales. </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About BioNTech</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing </font></div><div style="height:59.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.83pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">www.BioNTech.de</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Crescendo Biologics </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapeutics.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s ability to develop multi-functional Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-based formats can also be applied across a range of non-cancer indications. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beyond Crescendo&#8217;s proprietary pipeline, the Company has a global, multi-target discovery and development collaboration with Takeda&#59; a clinical development partnership for CB213 (a PD-1xLAG-3 multi-specific Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) with Cancer Research UK&#59; and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">), which has recently successfully completed a Phase 1 clinical trial. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For more information, please visit </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">www.crescendobiologics.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and follow &#64;HUMABODY.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BioNTech Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning&#58; BioNTech&#8217;s collaboration with Crescendo Biologics&#59; the ability of Crescendo&#8217;s Humabody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> V</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:1.41pt;vertical-align:baseline">H</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> discovery platform to develop multi-specific immunotherapies, including cell therapies&#59; and the ability of BioNTech to commercialize these immunotherapies, if successfully developed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For a discussion of these and other risks and uncertainties, see the section entitled &#8220;Risk Factors&#8221; in BioNTech&#8217;s Annual Report on Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC&#8217;s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONTACTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BioNTech&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media Relations </font></div><div style="height:59.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:120.83pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jasmina Alatovic </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+49 (0)6131 9084 1513 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media&#64;biontech.de</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sylke Maas, Ph.D. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+49 (0)6131 9084 1074 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investors&#64;biontech.de</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.074%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Crescendo Biologics</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michael Booth, CFO</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+ 44 (0)1223 497140</font></div><div style="margin-bottom:0.08pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">investors&#64;crescendobiologics.com</font></div><div style="margin-bottom:0.08pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">media&#64;crescendobiologics.com</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.932%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Instinctif Partners</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Melanie Toyne-Sewell, Katie Duffell,</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nathan Billis</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+ 44 (0)20 7457 2020</font></div><div style="margin-bottom:0.08pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">crescendo&#64;instinctif.com</font></div></td></tr></table></div><div style="height:59.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
MB5!.1PT*&@H    -24A$4@   -T   "3" 8    *EAP&     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  %Q$  !<1 <HF\S\  ",C241!
M5'A>[9T)=!1'FN?IZ9YN=^].C]_KM[/=,[L].S-OWKS9V7TS\Z9W>MI'8V-C
M<]_W:2YS@XW-#08,V!@?&,Q]VX YS8TYC,5]2>*2."TD<R,0 B$N(2&^C5]4
M)A2EJE)5J90JQM^/%T]45F969F3\XXOXXHO(2J(HBJ>HZ!3%8U1TBN(Q*CI%
M\1@5G:)XC(I.43Q&1:<H'J.B4Q2/4=$IBL>HZ!3%8U1TBN(Q*CI%\1@5G:)X
MC(I.43Q&1:<H'J.B4Q2/4=$IBL>HZ!3%8U1TBN(Q*CI%\1@5G:)XC(I.43Q&
M1:<H'J.B4Q2/4=$IBL>HZ!*4ZZL/2OZ6X\ZGZ+BY.T.N+4^5!_>+G2U*(J&B
M2S#NY]^5[VJ/DWV56MB4/6&3\TUD7)VW2Y(KM3;'-I<3+[XOA9=O.-\HB8**
M+H$HOGU/3E098P334O;_>5?SMZT<?_X]Y]O(R*@[WAS7VCF^E1S]W3 IRKWE
M?*LD BJZ!"*KS0PCE!96,*3D/VEG11@-&0T_,Y:NK>\<3W>S LXPEE,>/'#V
M4"H:%5V"<'7^;BN0_;_T">ZAZ%[ZP-DC,C(:37PD.B?MI9DZ/KIFJE)^J.@2
M@/LW[LCAO^TK*3_M\)A8XB6ZE*<ZR<&_Z"F%%Z\[>RD5B8HN ;@\<;.Q1KY^
MG'^*E^CV/TW_KJ5<&+;"V4NI2%1T%8WI:QU_9I0D_[C=XT(Q*6ZB,RGE3SM(
M^C\-DN*"0F=/I:)0T54P=X]?E /_M;.DFA0H%)_HQCI[1L:IQI."BF[_+[M(
MRD_:R\T]IYP]E8I"15?!Y"[<:YI^;4J*Q"2LW_$_ON_L&1D9]288T;T6_'R5
M6LOE"=\X>RH5A8JN@KDP<I41G6]<+3"E_N)U.?CK7E*4D^_L'9[BNX62]G?]
M)/6I3D'/A^C.]E[@[*U4%"JZ"N;,&PM"BHZ4;*S@Z<YSG;W#<V[@4DD)UK1T
M$LW.K#;3G;V5BD)%5\&<Z34_K.@8MTO^T6N2V6**W-R58=W^A9?R'B7S^59R
MEGS?:;:DF#[@_C_K$OP\)B'@S%;3G%]6*@H5705S?LA7X47G)*Q4ZE,=Y>!_
M[R4'?]/;-#M-LG][2>K/.]GO<98$.]9--"]/=_W<^66EHE#153 YL[99,003
M28EDK!C]O!(IC'7S3\1B7AJSSOEEI:)0T54PMU*R)/6G'<,V"^.5:*;>V)CN
M_+)24:CH*I@'!45RY)\&V<'K8$*)5\*C>>BW?:3HNLXXJ&A4= G ^<'+3-.O
MI0W7"B:8,B=SWF33M(S4"ZJ4+RJZ!*#@=(X<>+J;[9\%%4T9$]$N.&'NI)UU
M?E&I2%1T"<*%X2N,M7LTERYNR9E3=[K'/.>7E(I&19<@$$UR[#_>-<W -E8H
M0044;3+GP7F2_H\#35_NMO-+2D6CHDL@"C(OR^'_^:852IF%9XY/^7$[.?"K
M;G+[T!GG%Y1$0$678-Q).R>'_^;MR,?N0B0LYJ%?][11+$IBH:)+0.Z=RY63
MU3ZR?;&4/VT?5%2A$F-^''?\^=%R]^0EYXQ*(J&B2V"N3-LBZ?\PP(BHM;5<
MJ3_KZ)MW1[@7:ZF8OT2C, 9'&!@1)VE_VU>R/]FH:UXF,"JZ!*?X5H'D+MAC
M)Z>F_7T_V?]GG>UD5":XIORXO:3^E\Y6:"R]ES-[N]S/4X=)HJ.B>X) @'>.
MGK<K/^>M3Y,;2<?D3OHYN["1\N2@HE,4CU'1*8K'J.@4Q6-4=(KB,2HZ1?$8
M%5TY453\0 Y=O2<+3MV4,6EY,O3 =1E]Z+K,/IDON[+ORHU[%3N.5E"4+V?S
M=LF!"S-E>]:[DG1J@/D[4@Y>F"WG\_9*X7WUB)87*KHX<R*O4/KNRY5_6'I>
M*LWZ7BI-S91*4_P2GV=DR6\6GI4VVZ[(EHO>%NXSUW?(RJ/MY),=?RG#-E62
MP1LJR2"_Q.?AWU22\3O_6M8>[RH7\_<[1RKQ0D47)ZX;R]5[3Z[\;(X1&N*:
M8?[./BV5Y@1);)_I[#<]2VIMS);TZ_><,Y4/N;>_DT6'&UBA(2Z$-?+;2C(J
M2&([W_OV^Y&L//*:W"RXX)Q)*2LJNCBPYTJ!_/V2<U)ILA$1UBV8T$(E!&C$
M]PLCUIFFZ5D>',G^4MY/^G,9M-X(:G-PH85*[YK]!YKC/MKV&\F\NMXYHU(6
M5'1E9/WYV_+SV49HT[*"BRK29"W?*1EI^GWQ)/GLIS)D8R499BQ7,%%%FMXQ
M%G+8IA\9 <]WSJS$BHJN#"3G%,A3",XT$8,**=J$E316;^+Q^+PG//W2/-M'
M&U%&P;F))B?BR\S=X/R"$@LJNABY45@L_XLF95DM7& R%N]',[-DGQ%T6<BY
M=<P(Y6=6*,$$%&M"=&.W_DKRM8\7,RJZ&.FQ-U<J33)]N&#"*6LR0OZ751?D
M?AE>$S[O0&7K" DFG+(F^GC+TYLXOZ1$BXHN!D[=*)2?X*6,UFD233+-S/FG
M;CJ_&!T9.>MLLS*88.*1<,;@!;V8G^+\HA(-*KH8Z)MBK!R>RF!B(2%&FIU3
M3<)!$FR?TI(Y_G=K8FO"+3A8-6;1T1SE6'>\+M@^)*SHJF-MG5]4HD%%%R5$
MFOS=LO.^<;A H<PRR5BHI^>?D5K?7)8&25?DM_3[$%^H,;M0B?V->-.O13=^
MEW?WC+R7]%/KZ@\FEG!I\$8&Q?^'+$MO),O2&LJX';^VX@KFB$&0'V__E13<
MCX_3YX>$BBY*#N<6^"Q9H(B,L/[$;.^Y^ZJ<OUWD["V27U@L?9.-98S%X6($
M_-FQZ KUD>P%,5DYAA76'>\J!45YSIE$[A3F2M*IP3(ZZ1=6?/YC? R@XU0Y
M?>U;9V\E4E1T43(O\Z85PT-A,%PP-5.J;[@D*5=#>QP;)%WVA8#YBZJT-"5+
MVN_,<<X0&9LS^D;M0$&D\P]4<<Y0DJNW3QC+UU2&&I$-->)TC\.ALO?L)\Y>
M2J2HZ*)D>_9=G^B,(!C,_D?3U%SZ?>DOY3A]LU!^/M<(*1KGB[&.KVS,=LX0
M&<N/-(O*TM$,';'YQW+E5NEO\SEU=:/,V/?O5M2D_D9TW^6L=KY5(D5%%P/3
M3^9+K:\OR=C#U^5.%'Y]9AJ$=< $)B.ZY]9%MXS>DK0Z48D.:[7A9'?GZ$AX
M(*GGI\J\ _4E^=P$9YL2#2HZ#[E55"Q_C6,EF!,F6#*B>W%]=*+#"1*IZ'S.
MD/]F^FY7G:,5+U#1><S$X_D^;V8PD04FLU_3K5><(R-CPXGN$??I$.>.K!'.
MD8I7J.@\YO"U>\&]G\&2Z3N..!A= '3JN<D1B<[U/IZYMM4Y4O$*%9W', W(
M#IA'(KKI69)T\:YS9&1DWSQDQ]4BF<+#,$'&U;7.D8I7J.@\IO>^W,B:EZ;?
M]U>+ST7EJ($'#XIE^M[_8ZU8,*'Y)YJ7*XZT<(Y4O$)%YR&+LV[)3R)M6D[.
ME$'[KSE'1D?RV?'6*QE,:/[)C:%,/3?%.5+Q A6=!YR^623MMU^Q:Z-$-$YG
MFI^_G'=&LN_<=\X0'??NWY3Q._\J(FO'.!T#WHL/-Y2<6T>=,RCEB8JN'+EK
MFH;O'[HN3W]AA,2 >B06CF2LW*0R3F0]=GFI=:A$TK?#J>)SOCPEFS,&R-VB
MV"RL$ADJNG*"*)7_O>R<3VS1S#28E"D-DZ(;)@C%UR>Z2/^O2XHL5!IA!$JS
M]-,=OY4#%V8Y9U'BC8HNSERX720U-F9+I6E&;-$NXV L7.5UE^1.41EFK_J!
M4V7)X08RP @I$HOG)G?%L-DIS]E5Q)3XHJ*+,ZVVF;[;9Z>"BRI4PA(:P37\
M]K+<+HKO(K0(;\VQ3M:"(:9@(@N5^JZK) L.ON*<28D7*KHX4WOS99_H(NF_
M.6*CS_=Q^J,I->4!*S=_M.W7$8N/?EX_TS2=F_JL<P8E7JCHXDS:M7ORK\O/
M^YJ6].<8D^/_TXW ^,N\.K:;YN=OOCPK;^[-M=Y-+[A=>%FVG!HFXW?^C?58
ML@[F$-.,Y/]X.OG+V!W;^3QI]_^5\S?V.D<K\4)%5P[0(]N1?5=&';HNC9.N
MR!_67I1_7GE!_M_JBU)KTV7IEYPKJT[?EKP*>I]!4?$=.TUG2^9069+60.:D
M_$%F)O^;L6K/R++T)K(]:Y2<OK[=W$=L0Q9*>%1TBN(Q*CI%\1@5G:)XC(I.
M43Q&1:<H'J.B4Q2/4=$IBL>HZ!3%8Q)*= 4%!7+VW#E)2S\BJ?L/R.'T=#E[
M]IS=KB@NA]/2Y<+%B\ZG)X^$$-W>O<DR]L-/I,/KW:1^X^92LTY#J5ZKOOG;
MP'YF^]B/QLG>?<G.$<H/E1T[=LES+U:5=AV[R,V;L;W5J**I4-&EIQ^5M_H.
ME%=KU)677JTI55ZI*2^9]$KU.E*M9CUYI4:=Q[:S'_NG&TNH_#!9N&B)O/!R
M=:G?J)F</_]DOIBRPD2W9.E7UJ(AL*K5:TNC9JUDV(C1LFCQ,MFZ;8>Q:BFR
M;?L.N]^(4>]+D^:MI6JUVG;?&K4;V.T/'L1GWIGRY+!TV7);"3<VY>7BQ>@6
MXDT4*D1T,V;.MI:KFFE"UJ[72"9/G5YJK44&3S?'U:G?1%ZL6L.*[\J5Z%ZN
MH3SYJ.AB8-&2I2;3:MCF8\NV[>7 P4/.-Y&!DZ5[KS[RZ81)4EA8Z&Q5?BCX
M1%=#11<IAPZG&>M6SZ96;3O(F;-GG6\4)3)4=%%05%0D/8R%PCE2IWYC.7KL
MN/.-HD2.-B^C8,NV[?)RM5K6&3+WB_G.UOC!N-[R%:OD[MW'Q_1.?I<AZS=N
MDB\7+9&%BY?*QDV;)2/CE/-M<$YE9LG&;[ZU^W/<^@V;Y,3)Z!?HR<[.ENT[
M=LG2KU;(@H6+9<6J-;+_P$&Y=:OT]]GY<^_>/=NL7K/V:WN>Q4N_DJ2MV^1<
ME-Z[$R=/VGMQ\V*3N<=,<Z^E45Q<;//MVZ2MCSFO&%/=_.T6Z_SBG!LV?B,9
MI\+G;3C(=Z[IL7P_\7B^1R.ZRU>NR(Z=)O_-,>3;RM5K8\K_>..9Z(8.&RDO
MO5I+6K1N)S?R\YVM\>'Z]3S[$/[M]\_9AP9;C<A[]^DKM>HUDI?-[U:I6L,F
MA%^K;D/I/VBHY.;FVGU=]NQ-EK?Z#;*6F/T>'F..KU6WD?1Z\VU)VK+-V3LT
M#.B_-^8C:=2TI?7.4DAP_ECGD>G+MFG723Z?MT#NW+GC'!$<"CL52:<NW:W'
MEOSC/#2O<"35;]1<WAD^2HX=/^$<$1S$TO.-M^T]<"_V'-R7J0!Q3+UM[CG<
M&.CAM"-2N<JK]OHO7KQH[V_XNZ.E7J-F]AS^>5O;Y-W;_0?9PATI_#;7X)_O
M7*.;[UP[]P K5Z^QWX43'=?WP8>?V'U\^>\['\-/=&UL_G]1>OZ7%YZ(#E$T
M;_6:?6CCQG_F;(T?9'[#)BVM%?W"%.89,^<\'%[PB:R1'7+@(3!,P77\[C^>
M?UC0J+WQH-+TY3B.8;_&S5K;XVQA]3L? _58GV#LV;O/7@L%AOT168/&+:1I
MBS92KV$SWQ )!=5<0^=NO20KZWOGR,?)S;TF_08.L?NYQR"0)N8\G)_"X[O6
MVE+35"++5ZXN,81") ^%CVOV77OM$GGA?L<8Z-3I,YTC'V?GKCTF;^I:D7\\
M;H*M..UQYGS5:]<WE4LKFU>^\_GRB?O&6H7C@?DW9=I,7[X[>5LC:+[7L?DY
MU>P[_\M%]G,HT6TQ+8"&35K8"HKKL_EO/C=MT5;J-FQJ?X?C$6*7[KWE])DS
MSI'>X8GHTHX<-0^D@<V$;S;'_\7PERYEVP=%H6[:O(U]^*_6K"O-6K:5V7,^
MMX/IV=F7Y:+9[]"A-/N@9\R:(W?N^MZ(\]$GXVU-R /".E'X#ATZ;,_+<33M
M9L_]PISO-7/>>O:!#3,U_?W[CZ\A\IUIRE);$TV#*(:/?,\V+\^8FI?AC4PC
ML'5?;[ 6F()&XAJ_"VCNYN7E2=<>O6TA9)_VG;K:<<D3)T[:)A/-RMU[]LJ8
ML1];P5' $";7ZH)G=\BP=XW5\ 45M&C53N9\/E_2S;/PY<4E.6CN<<K4&;:0
M<N_DP:<3)CIG>,2>/?OL]PU-WO![-<RS)"'H?<DI<N'"1;EDFM(XRB9/F6Z?
M WE /BU:LLPY2TG&C9]H?K/ZPW/S7+@FGA/7R'.;/7>>K;#)=YXK8N3\P42'
M->2Y,Q3%[X\P^;]M^TYK^:[DY-CFZ^HUZZ1';Y]O@3RC J&9["6>B&[+UNVV
MAN&!\=#CC;_H&C1N;C/TS;?[RWE3&$ICZ;(5MK#Q4*GY,K-"]W$H7)R70LPQ
M"-&?,1]\;*THPEME^@^A0*P<2Y[0))XT>9KSC0^" 6@*<1_OC?E0;MP(W1S'
M6K?OU$5&COY [OK%J$Z;/LMW7^9::;J11Z'(.)4IKW?M80L_0@F\]H>B,Q:V
M;H,FUF)LW;[#^;8D/&,*LUOY4&D%LM+T;VE&<M[.W7H:060ZWY3D@A$7D4CD
M!\\WF.AX;G7,M2$XKH^^9B@*[Q7:BI6\P>KU?.,M*0C1<BD//!$='6R:!W4;
M-)53Y@''&W_140-C)2+I+&=?OORPEF_;_G6Y>O7Q/EXP."_B1*3T7[X__:AY
M0@U*01\X9)BS)3S+OEIA^S_4P"Z[=N^Q32H*Q/ 1HYVMX2DN#K"XQG+ZK'T]
MZ=[KS8CZ+EC0UJ]UM,?0%/;O[[JBHYG,W\U)H0NT"]YIGC>MFX&#WW&V^LBY
M>M5:+'Z+_E5.3NFO7[Y]^[9TZ_F&?;[U&C8O(;JAQJK;YFGMAK)SYVYG:W@F
M&:N,D!'_5Z;O[!6>B.Z;;Y-L0:I=K[%M(L4;5W0\9 I;I-9TP<)%MF:G-J:Y
M%BE'CAXS_8V&]MBIQJ*X#!CTCME64SIU[B[??W_:V1H=@]\982LH"GXDE4 P
M)DR<;"TN^7T\BOS>OF.G%17'XG%U<46'Y1HT=+BSM70F&@N.$+".9\X\&I-=
MLM0WUL8Y\2Y&"D(FWWG._J*C(J?_A\!ILD;*/=,$?[U+#]OBH'_M5;"%)Z)+
M2=UO"S:=<6KR>..*CO9\OP%#G*VE@P>36@[O6+0,,M:,8[%N>!F!RH5@7(1/
MYYT"BILZTL#<W&O7;!^/0C_^L\G.UNA@/+1+]U[VVH8.'^ELC9QN/=^TUAKQ
MN[BBHU"O6[_1V5HZ]/$0*L>YWD<8-&2X%5U7TV)P\RY2!IAG1BO 7W3+EJ^T
M>8:G.MJA'89?Z!-3094VE!0O/!$=<Y]HFI Q<TUG/MZXHL/*S)S]N;,U/'CV
M.KS>U397F";RKNE'X0:/)-'GPHU/[4HG_]JU1^\%IZ^&>Y]"S_5@X6G"TN2D
M'W/NW'EGSY+@^G=K;'?H(UIHJN&IXSSTT[C68/<0+)$'KW7H;/.DD[$ ;LV/
MZ&@*(J!HA@+.7[A@^X'DP[*O5MIM>'T[FI; BZ9RPH$5+7,^GV?/9T5WR2<Z
M0@(Y'\_QKN,<BQ3FYO&\Z-L1:.\%GHB.V@QK0K.INZE)HZW=2N.AZ$Q!Q\L7
M"?DW;]H^3%W3#\05CX6*)EDOF2F(].OH#_E#;4O3BL)%0:6R(='4P@(.,'T<
MG!5Y-QY_!QUQJ.Q/3<[00RS@/,(#6]]4<M3\+[Q<K<2UATLX(FAN49FX?4%7
M=!1.O(N1@BB8/6*?R[+E=MO-F[=L/PZ13)\YQVZ+AJ^,5<-*<EY7='AQN4]B
M<J.=>4)P ,U5K!V#\5[@B>B ,1L*'DW,;:;O$$]B$1V6#E<\'E7$UZ?O .N9
MC#B]U=\VQ;!L]^\'KT3XC=3]!TV'O:0 22U:MY==?GU)^BQ<3V!S+!I\EJZ-
M;2YAM?J\'=M]X=5U>22Z^E$%J-/"<47GGJ_@'BV,;E9TT?2_7+Z8]Z4]7U/3
M#+]ZU>> 8>R7\W'>:%<9.&+Z_W0'J&@8X_,"ST2'-XS"@(6(]ZS?6$0']/^H
M-7O%T*>+%I\ #UB/&8X6K :6$B?#]Z=]3A<$@U</03)^%@OTZ7 *T 0C"B@>
MQ%-T8/O2)M][]G[+V1(Y=NS1W%L7<X_<*S 6R#:&#++"#/D$8\7*U=;*T1R/
MQNE4%CP3'?B:!K[Q)R:LQJN9^4AT-:,2W1?S3:UI'CX"B*:O4E80():,9B!-
M.@;J7:@(:(:V;-M!\O-CJYBP( B7\:JL&+VH_O@W+V,37<W'1#=_ 5[CFC::
MA8HH4HC>H9+BWNC'N= 7YMKH/X>*J@D&Y8\@?%H6L5C)6/%4= _,3;HQF)AS
M.NZW;T<7_U90<,_VA_R]5+&*CL%NIOU3H' <1%+(&:=[9_A(&3EZ3(G]&:K@
MGH(-!@<#B__BRS5LG\2%05T[,&XZ]A]^_*FS-3HHA!1H6A5OF69SH6,1PD'$
MS-O]!]NF6F#AB[?H\#JZ^?YZEYZVGU<:!!0PR,\]<6_'_>)-Z<<QWDF9(C"!
MJ*-(H*E*/F.)%WRYR-E:_G@J.LC/S[?-"E]L8AWIUJ.WI*9&5MO1B<<A\\P?
M7Y*6;=H_#..*570P;\'"AQ$I]&?<SGDP? 5SD-F_NCQKKB'PX?8UA9:83CRU
MNW>''_>;;WZ7_AOGFF<LK@NU+S&7U-JT"'#(A!L_HDF$6/#J^8>E,>2 %><<
M#!U<N_[(PQH(\8<,,V!UR0O_,36(M^B ^W<C9NA/7[X<^CWK-V[<L-Y5_ $(
MQ-_*N1PY>M2(L8'M-S<V3?3DE/W.-\%9N&BIV;>>_?V.QLIY.?/ <]$!L85N
M,"\U%QW9(>^,D*_7;[3>I+R\&S8"@<RF2<&T$J+I:7>3210."I);@\?:IP,*
M.=:) DK!:MZZG14BEI2A@.NFL!)3B2.HE8W8, _>[#MXZ(@2[FDB;ZAM&9-$
M4!^/&V\KBFO7KMF'2I]M;W**+4#TY]B/<;G  D?<(1X^:F%$P^P&AA"H$#@/
M^8,UFS9CM@U"KOQ2-7L^QOE<\#QBY;":Y!E.%::X,)!\W>0_^W(.8AOI1W(M
M5 !85[>OY!+O/AV0[\1&^O*]KK1JT\%.$2*<B_X^U@_Q,\S"T Z"XUYP]H2*
ML%FQ<HUM16$)<20A3H8$>(;DFV^JSVX[?$.>\+OD7RS3MLI"A8@.>+"SYGQN
M.[]D)C4[!990+F:5MS.%I+7Y2S.$[5A&MY_"<?ZQ<C17Z!_Q<!<M7NILC1PL
MR0<?CK._04&GC<]U$3^(1:4?P38$P+72M*12" 85!"YHSL4]4:%P#@H] J-
M8.$I'#B60C5%&<\CW,RU5A0ZQJ8X#]Y6ABKL-7&])C%',;"/3//7=3SX]B-_
MF]KKX=XHF%4)JG;N>;PII(%!W+#+F66 %8FF#V;'Z9JVL,]E\9*2E2%C=N^;
MIK5M3IM[Y/IXWH3DD6@Q<&]\QST0D%#:M+ 5JU;[/,#F7-P3$2QN_C-^2>7$
M_5*6*&?E$0M<&A4F.A<L&_T(,H8,(3-H=N "IK]#9E,+DT$TF8(Y!I@&P\/Z
MW>^?MS5CK&!-B)) & ^OPR3^3].*P-QUZS<X>X<&:\(L!'?\QW<>7],-,5*Q
M$,CL'SL8C-NF1F>PGS$S"@J%USV/O:8Z#>2-/OWLNJ'A8/(LUH+\)3\?WI<I
M[%0*!/R&&QC&NCW_0E7[3**9\4^,)2*GR;UJ]3IG:TD8'[,!U^8YV^MSFKG\
MW[721)U$.@9'F![QGE0JW*/O?IW\-T+$^F(%8PVS*RL5+CH7!HJI1?%P,FA*
M7X:_?-Z__Z#M"X8C:<M6F3%K;IF'(JCITTR3A,FC%/A9)N%69EM@LZLTB+]<
MNVZ]]4Y.G#S56F@*V-DP42G!H'E$7"0=?\;\B/?D^HX>C5P .$<.'#AHFYCD
MT^PY7\BJ-6MM$[,TN&_<\CR+8)8P'-\F;3'YR',)WV>BM8&XL8B3I\ZP\QN_
M7+C$3AV*UMGF0EC7JC7K["IRY/\<TY3&416N_^@%"2,Z1?FAH*)3%(]1T2F*
MQZCH$@3Z7"SE0/]-^<^-BBY!P"O+H+]_ '1Y$SC$H'B#BBY!0'2,+44ZI0>/
M(E.$@D5G1 (>6=SJT4Z%B84)$Z?88 BO9F8G.BJZ! '1,0B\)\)W\.&Z'SQT
MN"W0L<#0 X/MT0X!Q +#/U00A44J.E#1)0BNI4M.]<4,%A7=M^%M+)X4BS5B
MI6N6Q6/-T6 P=D7 03#1$=/*L83K10+3MKC.:,<Q@=]GW*RT@6H&V@GC^L_0
M)%;1)0B(C@#<W7OVV5D4A&D1&UC-)"(RUGZ]WMGS$0Q6L[RA/P0'?#9IJ@V+
M(\*#>%56K6:RIC_!1$=,)^M>VA72.+9>(SO5*-0 ^J[=>Z5;#]\*7>S?K%5;
MNW)UH/B(=O%?Z @0#R]X)!*)\#(;\=.UIUV9V[^283";:3?$?5:O[8M,(K[6
MBV9Q>:&B2Q"(7F%-1P*="7\B3(RP-")8AKSSKOS^V1?DL\E3G;U](,;A(Q\M
MTT=@=?N.76S,X91I,V3SYB2[-@F%MG*55^S"JRZ!HLO)R?$MP5>CKDR;,<L4
M]B2[Q *_08!YX&II+!_XA^=?E#?Z]+4+N+*(,*L_/_]B5>G;?]!CTX,(*.>^
M7! E2^8]6_DENV M]\E[&M[J-]"&C.W<Y5M"CV7QF,W1?^!0Z]EE/Z9!X7 B
M#C/:]5 2!15=@H#H"+*FT >+@R3L"^'Y+Z+*>C,??/AH+AZS%[ 8K"3M#X6<
M2</$7M)D!5=TQ<4^BT$AYO<#7U]&4#)1^001(TP@_O*Y%UZ6R4;8@3 9^(]5
M7K7"=6$9>F):79C%\6SEEX,N>[A]YR[;C*0RH,\YQN_^7%BVK_>;?:UE?A)1
MT24(B(Y@Z'!+[S%?CWEO;M/*7W0L'<Z,A/4;O[&? R'VD>!FYMV!*SK@MUG8
M)]3+4>@7(ECWW02CWA]K9X"$@GA5@HW=>%E_T;$*-3,/6)LS'#0_6=ZP7<?.
M=CI.N%6NGS14= D"\P99IB'<.!TO">%UT6Y0M[_H:#IB)?W?9Q (;GN\B$ P
MN2LZEHZ@7W4UX"U&_C";@?EOT*Y3E[!#%4R7X5Y..O/4_$5'Y4"D?W)*JOT<
M#E;/[M'[+7GAI6IV>A7-5%H!7DXX+0]4= D"\^?P7H9;C-<GNL8/(_;]1<>+
M2AARX.4;H6#6N[M"L[^EXUUW6+)PRYLSD99"#_01/_DT]-N7F#C*E!IW&I"_
MZ+A/!!GNU5R!(%XFVW;HU-5.^V$:%[,7GE14= D"CH<F+5J'71>%-4)X3X/K
MN/,7'>M=4M!#S2=DN0:\H;QJ"OQ%QU0C"G.H=1]9I@*AN![(L1]^8B>$!AMN
M ,Y-<]7U>OJ+CCXBDW<C6?\EF(>2Z3HX4_!FNGW,)PT570+!G+4_/%\EZ/J+
M3.+$D9+DMQYFH".%PH@XCAPYYFSQP2QWK!Q6DO$N>.1(\8U[8<48G@A<AHZF
M+$X+EC5PXT(S,C+M$A$()U!X[OL0&$8()CIP/9^; EZ;ALA8\H(Q/\"!PR!^
M(#B5:')&NEQ]HJ&B2R HP!1^A#?JO0]L 5S[]0;K641PK)GI#^MGCGIOC//)
M)Y">O?L80;QJ!4BH%Q-G628",;H#[\"Y6,#'%0V3B''2,,-Z[,?C['HC,V?-
ME2;-6UD+&;BR,U;QN1>JVJ8FWD@JA6$C1MG9[2RLRXQQ5W2CWQ]KFX8NB NO
M),(CJL9]/33C=+]_IK)]]P7P&N1G_EC%7A<36A$K:^DP9,"DU"=UK$Y%EX#P
M5ANL$ /..#A8B7K]AI(O[D"@> K]H?GV^;PO[;@8R\4W:M;*.D "W_C*&!C>
M4/^"R[@7*U8S7L>QN.P1_^F U<%<Z+OQ0@_&%QEN0&PL+H6U9*"?91. <[)\
M12#,JD=H'(LEQ1H'KL'"$ 3-:OIQ[,<[)!@7?))1T24H-/L(CZ(_%0JL5*BP
M*,3$(CZ!:UBZ\'VHL*W2C@V$U;G\UP!EV04L)B^;!*XQ5/\/>*]$J(6>7/@^
MUL5W$PT5G1(UB @+&VQEL/OFN]Y]^EE+[?]F6.41*CHE:K!:Q',^5_EEV^]C
M75#6N"06DS>_TJ>,9!SNAXJ*3HD)EK>?/F.V7<:<2!H&YFE2XE@Y&,6"M#]$
M5'1*F2 \"V\CD2+'3YQX8CV*7J*B4Q2/4=$IBL>HZ!3%4T3^/^!UZUS#2&1*
,     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M"&-NC9069CS&A5<="%$(W3^ ^NRY)57H_@DI-XN-]2R_+TWWGQ/&P*3,\ &
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MGSVWI K=/R'D?[)VN!.?JWRB^W>'A]\)>5.R.5U/AVT12DMU/-OMG<?;!1!
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MSR9L%F98;"U$AN;]O_[Q\-B)-R4 ?!G=/P"@*'SF\$N9WUY=.]QIG%0,10$
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M .,B^!D8C^>T/MW_6_SZQP]VR;VG=;42KR=DT/WGA.X? *!/\%<.G0ZR  "
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M=/^9^=CY9W4\:__0KA/VTH?'3KRJDT3WGQ.Z?P" %[)C+EYX / :.E/?=/]
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MZ?ZAI]L[SZ_^;[86'AX[\:H.0_>?$[I_ (!37A[.#MD_:\9+#Z \.E/?=/]
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M P!<VSC:M8,C\5#_ V72F?JF^P<B]C!)%;I_0)?4P,-1C:US ^1HH[V&KQ_
M&V1N<SFS-YCAB,?B?R:[$U>?[A]^M&_W[)[C/:VKE7@]GZ'[SPG=/P# -8\O
M/,Q0_P-%TIGZIOL'(O8P216Z?T"7SK$YXZH-TKD!<K317J.Z/+7KZ"+[9\UX
M98 )<UK\A[0[=_'*.&=KH22A^\=KW'S\J3J>M?N/Z[2N5AX>._&J?D+WGQ.Z
M?P" =U*S<*\/]3]0&IVI;[I_(&(/DU2A^P=TV6,D81S5V#HW0(XVVBO-;Z_:
MU701ZG],D]0OMKPI:X<[\<KX9VNA)*'[QRMU>^?YU?_-UL)GZW^Z_YS0_0,
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M'@D/PC< "A3^XAM'N\JGY?H):U?(;SW:6BA)Z/XQ":VK%;NSD1%"]U\?W3\
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M2$6R?ZB'FS]_D5/ N&3_^9#]!X,V$2+V2L?##B=78Y[;B)DZBK'MM+X=#1I
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M.ZUO1X,&4 8Y3;3\+_N_N;];OF41\0?D\U-3++-2=;DQ0 L[LZ!U_KCH_HD
MI?@R^\V"\\5U]R\#@)>7I^>9G"_E37]&]R^#[\3(I4S^_<]=]X^#[X<V$2+V
M2L<#%)$W)&*FCCI7=II^C@8-H QRFFB9IN>_0L%"C+00/OD     245.1*Y"
"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
